相关临床试验
0
0 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
暂无批准数据
- Healthcare leaders at Florida Cancer Specialists emphasize the critical need for provider-payer collaboration to deliver high-quality, cost-effective oncology care while prioritizing patient outcomes. - Community oncology practices are expanding access to novel therapies like bispecific antibodies through innovative outpatient delivery models, though payer barriers and safety concerns remain key challenges. - Advanced biomarker testing, including liquid and tissue biopsies, is revolutionizing personalized cancer care by enabling more precise diagnosis, targeted therapy selection, and treatment monitoring.
- McKesson Corporation agreed to purchase a 70% controlling stake in Florida Cancer Specialists' Core Ventures for approximately $2.49 billion in cash to strengthen its oncology platform. - The acquisition brings Florida Cancer Specialists, with over 250 physicians and 280 advanced practice providers across nearly 100 Florida locations, into McKesson's US Oncology Network. - The transaction aims to advance community-based cancer care by combining operational expertise to increase access to high-quality, affordable oncology services and treatments. - Florida Cancer Specialists will maintain independent ownership while gaining access to McKesson's differentiated oncology care products, services, and clinical trial capabilities through Sarah Cannon Research Institute.
